



Sheep antibody to alpha synuclein (116-131): whole serum

| | |
|--------------------------|---|
| Catalogue No.: | S-024-100 |
| Description: | Alpha synuclein is an abundant 140 amino acid neuronal protein, expressed primarily at presynaptic terminals in the central nervous system. Alpha synuclein has been associated with several neurodegenerative diseases. A point mutation in the gene coding for the alpha-synuclein protein was the first discovery linking this protein to a rare familial form of Parkinson's disease (PD). Subsequently, other mutations in the alpha-synuclein gene have been identified in familial PD. The aggregated proteinaceous inclusions called Lewy bodies found in PD and cortical Lewy body dementia (LBD) were discovered to be predominantly alpha-synuclein. Aberrant aggregation of alpha-synuclein has been detected in an increasing number of neurodegenerative diseases, collectively known as synucleopathies. Alpha-synuclein exists physiologically in both soluble and membrane-bound states, in unstructured and alpha-helical conformations, respectively. The physiological function of alpha-synuclein appears to require its translocation between these subcellular compartments and interconversion between the 2 conformations. Abnormal processing of alpha-synuclein is predicted to lead to pathological changes in its binding properties and function. |
| Batch No.: | See product label |
| Unit size: | 100 uL |
| Antigen: | A synthetic peptide (CMPVDPDNEAYEMPSEE) as part of human alpha synuclein (aa: 116-131) conjugated to KLH has been used as the immunogen. |
| Other Names: | Non-A beta component of AD amyloid; Non-A4 component of amyloid precursor; NACP |
| Accession: | SYUA_HUMAN |
| Produced in: | Sheep |
| Purity: | Whole serum |
| Applications: | IHC with 1:1000 to 1:2000 dilution. Biosensis recommends optimal dilutions/concentrations should be determined by the end user. |
| Specificity: | Immunohistochemistry shows a high specificity for alpha-synuclein. |
| Cross-reactivity: | This antibody is known to react with human, rat and mouse alpha-synuclein. |
| Form: | Lyophilised |
| Reconstitution: | Reconstitute in 100 uL of sterile water. Centrifuge to remove any insoluble material. |
| Storage: | After reconstitution keep aliquots at -20C for a higher stability, and at 2-8C with an appropriate antibacterial agent. Glycerol (1:1) may be added for an additional stability. Avoid repetitive freeze/thaw cycles. |
| Expiry Date: | 12 months after purchase |
| References: | <ol style="list-style-type: none">1. Lundvig, et al Brain Res Mol Brain Res 134, 3-17 (Mar 24, 2005).2. Bennett, Pharmacol Ther 105, 311-31 (Mar, 2005).3. Vekrellis, et al., Mol Neurobiol 30, 1-21 (Aug, 2004).4. Martin, et al., Protein Pept Lett 11, 229-37 (Jun, 2004).5. Doherty, et al., Acta Neuropathol (Berl) 107, 169-75 (Feb, 2004). |

FOR RESEARCH USE ONLY



Sheep antibody to alpha synuclein (116-131): whole serum

6. Goedert, Curr Opin Genet Dev 11, 343-51 (Jun, 2001).
7. Saito, et al., J Neurol Sci 177, 48-59 (Aug 1, 2000).
8. Lücking C.B. et al., Cell Mol Life Sci. 2000 Dec;57(13-14):1894-908.9. Kahle, et al., Ann N Y Acad Sci 920, 33-41 (2000).
10. Clayton, et al., Trends Neurosci 21, 249-54 (Jun, 1998).

biosensis

FOR RESEARCH USE ONLY